Brief: Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs
12/01/2026 13:41
Jan 12 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMS MOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW SPANS NINE COUNTRIES MOLECULIN BIOTECH INC - PRIMARY EFFICACY DATA FOR MIRACLE EXPECTED IN 2028 Source text: ID:nGNX8nsQ5g Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM